. 2023 Oct 30;4(5):1082–1094. doi: 10.37349/etat.2023.00182

Table 3.

Treatment changes in LC due to the COVID-19 pandemic

NSCLC T1-T2 N0M0	Locally advanced NSCLC	Metastatic NSCLC	LS-SCLC	ES-SCLC
More use of 3D/IMRT RT or SBRT as an alternative to surgery	Less use of surgery	Shorter and more spaced chemotherapy and ICI regimens	More use of sequential CRT	Shorter and more spaced chemotherapy and ICI regimens
	More use of sequential CRT	Single-dose palliative RT	Hypofractionated RT	Single-dose palliative RT
	Hypofractionated RT	Less use of local treatments in oligometastatic patients	PCI vs. close follow-up	PCI vs. close follow-up
	Consolidative durvalumab Q4W	Less use of local treatments in oligometastatic patients	PCI vs. close follow-up	PCI vs. close follow-up

ES: extensive stage; IMRT: intensity-modulated RT